Ignite Creation Date:
2025-12-24 @ 11:56 PM
Ignite Modification Date:
2025-12-25 @ 9:53 PM
Study NCT ID:
NCT01660451
Status:
COMPLETED
Last Update Posted:
2024-07-17
First Post:
2012-08-06
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-11-19
Start Date Type:
ACTUAL
Primary Completion Date:
2016-06-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-18
Completion Date Type:
ACTUAL
First Submit Date:
2012-08-06
First Submit QC Date:
None
Study First Post Date:
2012-08-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-10-13
Results First Submit QC Date:
None
Results First Post Date:
2018-01-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-25
Last Update Post Date:
2024-07-17
Last Update Post Date Type:
ACTUAL